FDA Approves Generic Version Of Medication Amid Scarcity Of ADHD Drugs: “Opportune Time”
The U.S. Food and Drug Administration (FDA) has approved a number of generic medications (lisdexamfetamine dimesylate) for the treatment of attention-deficit/hyperactivity disorder in patients 6 years of age and older in response to the ongoing drug shortage for ADHD. According to the FDA’s notice, chewable tablets and capsules are both forms in which Vyvanse is sold. Dr. Barry K. Herman, a board-certified psychiatrist and the chief medical officer of Mentavi Health in Grand Rapids, Michigan, which offers mental health assessments, is optimistic that the availability of these new generic medications will assist to alleviate the ongoing shortage of ADHD medications. “Hopefully, manufacturing will now scale up quickly to meet this urgent need. The FDA made the review and approval of these generics a priority,” he told Fox News Digital. These generic medications are created to function and offer benefits identical to those of their brand-name counterparts. According to Herman, “Gen...